Summit Trail Advisors LLC Boosts Holdings in Moderna, Inc. (NASDAQ:MRNA)

Summit Trail Advisors LLC grew its stake in Moderna, Inc. (NASDAQ:MRNA) by 36.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,281 shares of the company’s stock after purchasing an additional 1,927 shares during the quarter. Summit Trail Advisors LLC’s holdings in Moderna were worth $303,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of MRNA. Blue Trust Inc. increased its stake in Moderna by 365.6% during the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after buying an additional 574 shares in the last quarter. Wilmington Savings Fund Society FSB increased its position in shares of Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after purchasing an additional 587 shares in the last quarter. Larson Financial Group LLC raised its stake in Moderna by 53.5% in the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after purchasing an additional 317 shares during the last quarter. Rakuten Securities Inc. lifted its holdings in Moderna by 477.3% in the 3rd quarter. Rakuten Securities Inc. now owns 941 shares of the company’s stock valued at $63,000 after purchasing an additional 778 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB boosted its stake in Moderna by 58.2% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after purchasing an additional 389 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analyst Ratings Changes

MRNA has been the subject of several research reports. HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price objective for the company in a research note on Monday, November 18th. Argus lowered Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research report on Friday, November 8th. Bank of America dropped their target price on Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a report on Tuesday. Finally, JPMorgan Chase & Co. reduced their price target on Moderna from $59.00 to $45.00 and set an “underweight” rating on the stock in a report on Tuesday, November 26th. Four analysts have rated the stock with a sell rating, fourteen have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $66.89.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the company’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the sale, the insider now owns 19,717 shares in the company, valued at $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 2,664 shares of company stock valued at $115,210 in the last ninety days. Company insiders own 15.70% of the company’s stock.

Moderna Stock Performance

NASDAQ MRNA opened at $30.53 on Thursday. The company has a market cap of $11.75 billion, a P/E ratio of -5.25 and a beta of 1.59. Moderna, Inc. has a 1-year low of $30.24 and a 1-year high of $170.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The stock has a 50-day moving average of $39.53 and a two-hundred day moving average of $56.11.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.